Print Page | Sign In
Steven Feldman, MD
Share |

Chronic skin diseases have a huge impact on patients’ lives. We can help make great improvements in our patients’ lives, if they will use the medicine we prescribe. That’s a big if. Dr. Steven Feldman has opened our understanding of adherence issues in the treatment of psoriasis, atopic dermatitis and acne. He is author of over 700 MEDLINE-referenced publications and serves as editor of the Journal of Dermatological Treatment.

Dr. Feldman is a board-certified dermatologist and dermatopathologist. He is professor of dermatology, pathology and public health sciences at the Wake Forest University School of Medicine in North Carolina. He earned his M.D. and PhD degrees from Duke University in Durham, NC, and then completed a dermatology residency at the University of North Carolina at Chapel Hill and his dermatopathology residency at the Medical University of South Carolina, in Charleston.


Adherence to Treatment

Poor adherence to treatment is nearly ubiquitous. Poor treatment outcomes and many other puzzling dermatologic phenomena are mediated by poor use of medication. This session describes how well people use their medications, relying on evidence obtained using objective electronic monitors. Practical ways to improve patients’ use of medications will be discussed. These measures can help dramatically improve outcomes of treatment for patients with many chronic skin diseases including acne, atopic dermatitis, and psoriasis. 


  1. Describe ways to manage difficult to treat psoriasis
  2. Describe how well (poorly) patients use dermatological treatment
  3. List ways to improve patients’ use of medications


  1. New methods of diagnosis and treatment
  2. Development of new technology
  3. Advances in medical knowledge


  1. Shokeen D, O’Neill JL, Taheri A, Feldman SR. “Are Topical Keratolytic Agents Needed in the Treatment of Scalp Psoriasis?” Dermatol Online J. 2014 Mar 17; 20(3).
  2. Heaton E, Levender MM, Feldman SR. “Timing of Office Visits Can Be a Powerful Tool to Improve Adherence in the Treatment of Dermatologic Conditions”. J Dermatolog Treat. 2013 Apr; 24(2): 82-8. 
  3. Feldman SR, Vrijens B, Gieler U, Piaserico S, Puig L, Van de Kerkhof P. “Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence”. Am J Clin Dermatol. 2017 Apr; 18(2):253-271.
Core Competencies: 2, 3, 4, 5, 7
Disclosures: Speaker: Abbvie, Celgene, Janssen, Leo Pharma, Inc., Lilly, Novartis, Taro; Grant Support: Abbvie, Celgene, Galderma, Janssen, Novartis, Pfizer Inc., Qurient, Sanofi, Taro; Consultant: Abbvie, Advance Medical, Caremark, Celgene, Galderma, Gerson Lehrman Group, Guidepoint Global, Janssen, Kikaku, Leo Pharma, Inc., Lilly, Merck & Co., Inc., Mylan, Novartis, Pfizer, Qurient, Sanofi, Sienna, Sun Pharma, Suncare Research, Valeant, Xenoport; Royalties: Informa, UpToDate, Xilbris; Stock Holder: Causa Technologies, Medical Quality Enhancement Corp.; Founder/CTO: Causa Technologies

2902 North Baltimore Street | P.O. Box 7525 | Kirksville, Missouri 63501

660-665-2184 | 1-800-449-2623 | 660-627-2623